EU/3/05/328

Table of contents

About

On 28 October 2005, orphan designation (EU/3/05/328) was granted by the European Commission to The Matthews Consultancy Ltd, United Kingdom, for (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone (also known as “depsipeptide”) for the for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).

The sponsorship was transferred to Gloucester Pharmaceuticals Limited, United Kingdom, in October 2008 and to Celgene Europe Limited, United Kingdom, in September 2010. The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in September 2018.

Key facts

Active substance
(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Disease / condition
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Date of decision
27/10/2005
Outcome
Positive
Orphan decision number
EU/3/05/328

Sponsor's contact details

Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
The Netherlands
Tel. +31 302844547
E-mail: medinfo.intl@celgene.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating